Stocktoria
Evolent Health, Inc. EVH
Evolent Health, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.9B | $2.6B | $2.0B | $1.4B | $908.0M | $924.6M | $846.4M | $627.1M | $434.9M | $254.2M |
| R&D expense | — | — | — | — | $15.5M | $15.1M | $19.8M | $18.2M | $17.2M | $11.1M |
| SG&A expense | $303.9M | $263.1M | $358.1M | $269.3M | $219.5M | $210.4M | $236.4M | $235.4M | $205.7M | $160.7M |
| Operating income | -$410.1M | -$40.5M | -$71.2M | $3.6M | -$42.4M | -$262.8M | -$308.9M | -$47.5M | -$72.8M | -$237.4M |
| Interest expense | — | — | $54.2M | $15.6M | $25.4M | $28.3M | $14.6M | $5.5M | $3.6M | $247,000 |
| Income tax | -$126,000 | -$1.4M | -$89.4M | -$43.4M | $483,000 | -$2.4M | -$22.8M | $40,000 | -$6.6M | -$10.8M |
| Net income | -$534.5M | -$61.6M | -$113.0M | -$19.2M | -$37.6M | -$334.2M | -$302.0M | -$52.7M | -$60.7M | -$159.7M |
| EPS (diluted) | $-5.07 | $-0.81 | $-1.28 | $-0.20 | $-0.44 | $-3.94 | $-3.67 | — | $-0.94 | $-3.55 |
| Operating cash flow | $38.8M | $18.8M | $142.6M | -$11.6M | $38.7M | -$16.2M | -$42.6M | -$20.7M | -$28.0M | -$35.5M |
| Free cash flow | — | — | — | — | — | — | -$78.2M | -$60.2M | -$55.8M | -$51.0M |
| Cash & equivalents | $151.9M | $104.2M | $192.8M | $188.2M | $266.3M | $319.0M | $101.0M | $228.3M | $238.4M | $134.6M |
| Total assets | $1.9B | $2.5B | $2.7B | $1.8B | $1.4B | $1.4B | $1.5B | $1.7B | $1.3B | $1.2B |
| Total liabilities | $1.5B | $1.4B | $1.4B | $957.9M | $725.8M | $752.1M | $569.0M | $532.9M | $266.4M | $287.7M |
| Shareholders' equity | $415.2M | $1.0B | $1.1B | $859.4M | $693.6M | $619.6M | $929.0M | $1.2B | $1.0B | $912.1M |
Growth · year-over-year · Revenue CAGR 24.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -26.6% | +30.1% | +45.3% | +48.9% | -1.8% | +9.2% | +35.0% | +44.2% | +71.1% | — |
| Net income growth | — | — | — | — | — | — | — | — | — | -148.0% |
| EPS growth | — | — | — | — | — | — | — | — | — | -151.2% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.